Bone marrow transplant for GATA2 mutations
Treatments studied
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This trial tests a bone marrow transplant (called allogeneic hematopoietic stem cell transplant) as a treatment for people with GATA2 mutations or MonoMAC. The goal is to replace faulty immune cells with healthy donor cells, which may reduce infections and improve immune function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 6 and 70 years old.
- You must have a GATA2 gene mutation or the related condition MonoMAC.
- You must have had at least one serious infection or have low levels of certain immune cells in your bone marrow.
- You must not be HIV positive.
- You must be willing to use contraception if there is any chance of pregnancy.
- You must not be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies how well a donor bone marrow (stem cell) transplant works for people with inherited immune system problems (called immune deficiencies). It’s for patients who haven’t improved with usual treatment or don’t have another good option.
This Phase 2 study tests a specific type of donor stem cell transplant for severe bone marrow failure conditions, aiming to improve cure rates while reducing transplant risks. It includes people with diseases like severe aplastic anemia and certain bone marrow disorders, especially when standard transplant plans feel too risky.
This Phase 2 trial tests a stem cell (bone marrow) transplant approach to restore bone marrow function and immune function in people with certain inherited immune problems. If you have one of these conditions and a suitable donor, the study may offer a path to rebuild blood and immune systems.
This natural history study looks at how GATA2 deficiency (a genetic condition) affects health over time. It may help doctors better understand complications and plan future care, and it includes genetic testing and stored samples.
This trial tests a two-step use of ATG (a drug that calms immune cells) to help prevent graft-versus-host disease (GVHD) in patients receiving a stem cell transplant from a donor. It may be an option for people with certain blood cancers or disorders who are getting a strong, marrow-clearing transplant.
This study looks at how GATA2 gene changes affect your blood cells over time. It is for people of any age who have a GATA2 mutation they were born with, and it does not test a new drug—just collects information and samples during regular checkups.
Hear when a new Immunodeficiency trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.